ASIX Stock Analysis: AdvanSix | NYSE
Chemicals | NYSE, USA | Market Cap: 438m USD | 12M Return: -14.2% | US00773T1016 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.27M
Qual. Beats: -1
Rev. Trend: 16.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AdvanSix Inc. (NYSE: ASIX) is an integrated chemistry company that manufactures and sells polymer resins, primarily Nylon 6, along with related chemical products. Its portfolio spans caprolactam (a feedstock for nylon production), ammonium sulfate fertilizers, acetone, and a range of intermediate chemicals such as phenol, cyclohexanone, and specialty amines. These products serve downstream markets including automotive components, adhesives, paints, coatings, water treatment, and pharmaceuticals. The company sells through both direct channels and distributors, marketing under brands including Aegis, Sulf-N, Nadone, Naxol, and EZ-Blox.
As a commodity chemicals producer in the GICS Materials sector, AdvanSix operates on an integrated production model in which key feedstocks like caprolactam and phenol are manufactured internally before being converted into finished resins and chemicals. This vertical integration is common among nylon producers, as it provides cost control over volatile raw material inputs. The company was incorporated in 2016, spun out from Honeywell, and is headquartered in Parsippany, New Jersey.
- Caprolactam and nylon 6 pricing spreads drive segment margins
- Ammonium sulfate fertilizer demand tracks spring planting season
- Propane feedstock cost volatility pressures gross margins
- Asian caprolactam oversupply weighs on pricing power
| Net Income: -17.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -3.17 > 1.0 |
| NWC/Revenue: 5.97% < 20% (prev 7.47%; Δ -1.50% < -1%) |
| CFO/TA 0.05 > 3% & CFO 85.0m > Net Income -17.7m |
| Net Debt (565.7m) to EBITDA (52.4m): 10.79 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.6m) vs 12m ago 1.30% < -2% |
| Gross Margin: 5.62% > 18% (prev 11.93%; Δ -6.31% > 0.5%) |
| Asset Turnover: 93.99% > 50% (prev 92.02%; Δ 1.96% > 0%) |
| Interest Coverage Ratio: -1.07 > 6 (EBIT TTM -10.4m / Interest Expense TTM 9.72m) |
| A: 0.06 (Total Current Assets 424.9m - Total Current Liabilities 331.7m) / Total Assets 1.67b |
| B: 0.38 (Retained Earnings 641.7m / Total Assets 1.67b) |
| C: -0.01 (EBIT TTM -10.4m / Avg Total Assets 1.66b) |
| D: 0.91 (Book Value of Equity 796.9m / Total Liabilities 876.1m) |
| Altman-Z'' = 2.53 = A |
| DSRI: 1.15 (Receivables 207.9m/174.9m, Revenue 1.56b/1.52b) |
| GMI: 2.12 (GM 11.93% / 5.62%) |
| AQI: 2.01 (AQ_t 0.17 / AQ_t-1 0.08) |
| SGI: 1.03 (Revenue 1.56b / 1.52b) |
| TATA: -0.06 (NI -17.7m - CFO 85.0m) / TA 1.67b) |
| Beneish M = -1.27 (Cap -4..+1) = D |
As of September 27, 2026, the stock is trading at USD 15.80 with a total of 222,509 shares traded. Over the past week, the price has changed by -2.53%, over one month by -3.42%, over three months by -19.63% and over the past year by -14.17%.
Current recommended Stop Loss: 14.90 (which is 5.7% or 1.4 ATR below the current price).
AdvanSix has no consensus analysts rating.
| Analysts Target Price | 20 | 26.6% |
P/S = 0.2806
P/B = 0.5492
Revenue TTM = 1.56b USD
EBIT TTM = -10.4m USD
EBITDA TTM = 52.4m USD
Long Term Debt = 275.0m USD (from longTermDebt, last quarter)
Short Term Debt = 42.8m USD (from shortTermDebt, last quarter)
Debt = 572.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 148.9m
Net Debt = 565.7m USD (calculated: Debt 572.9m - CCE 7.22m)
Enterprise Value = 1.00b USD (437.7m + Debt 572.9m - CCE 7.22m)
Interest Coverage Ratio = -1.07 (Ebit TTM -10.4m / Interest Expense TTM 9.72m)
EV/FCF = -38.96x (Enterprise Value 1.00b / FCF TTM -25.8m)
FCF Yield = -2.57% (FCF TTM -25.8m / Enterprise Value 1.00b)
FCF Margin = -1.65% (FCF TTM -25.8m / Revenue TTM 1.56b)
Net Margin = -1.14% (Net Income TTM -17.7m / Revenue TTM 1.56b)
Gross Margin = 5.62% ((Revenue TTM 1.56b - Cost of Revenue TTM 1.47b) / Revenue TTM)
Gross Margin QoQ = 7.38% (prev 0.94%)
Tobins Q-Ratio = 0.60 (Enterprise Value 1.00b / Total Assets 1.67b)
Interest Expense / Debt = 1.70% (Interest Expense 9.72m / Debt 572.9m)
Taxrate = 9.45% (5.14m / 54.4m)
NOPAT = -9.46m (EBIT -10.4m * (1 - 9.45%)) [loss with tax shield]
Current Ratio = 1.28 (Total Current Assets 424.9m / Total Current Liabilities 331.7m)
Debt / Equity = 0.72 (Debt 572.9m / totalStockholderEquity, last quarter 796.9m)
Debt / EBITDA = 10.79 (Net Debt 565.7m / EBITDA 52.4m)
Debt / FCF = -21.97 (negative FCF - burning cash) (Net Debt 565.7m / FCF TTM -25.8m)
Total Stockholder Equity = 806.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.07% (Net Income -17.7m / Total Assets 1.67b)
RoE = -2.20% (Net Income TTM -17.7m / Total Stockholder Equity 806.7m)
RoCE = -0.97% (EBIT -10.4m / Capital Employed (Equity 806.7m + L.T.Debt 275.0m))
RoIC = -0.69% (negative operating profit) (NOPAT -9.46m / Invested Capital 1.38b)
WACC = 4.77% (E(437.7m)/V(1.01b) * Re(9.0%) + D(572.9m)/V(1.01b) * Rd(1.70%) * (1-Tc(0.09)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 35.25 | Cagr: 1.19%
[DCF] Fair Price = unknown (Cash Flow -25.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.72 | # QB: -1
Revenue Correlation: 16.26 | Revenue CAGR: 0.38% | SUE: -0.06 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.04 | Chg30d=-110.59% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=-87.11% | Revisions=+0% | GrowthEPS=-91.9% | GrowthRev=+9.9%
EPS next Year (2027-12-31): EPS=2.38 | Chg30d=-18.46% | Revisions=-40% | GrowthEPS=+1189.2% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -40% (up=0, down=2)